Pharmaceutical company Lilly China will double its staff to 2,000 this year even as experts debate whether the economy has bottomed out. "A large portion of the hires are in sales and distribution a
s we expect to do a better job reaching patients in central and western areas of China," David Ricks, Lilly China president, told China Business Weekly late last month. But he added Lilly China is growing in all aspects, so new employees will be needed in virtually every function from manufacturing and R&D to accounting and operations. Lilly China is not the only pharmaceutical firm expanding recruitment in China even as global workforce numbers are stagnant or even dropping. Swiss drug maker Novartis Pharmaceuticals expects to increase its 2,700 employees in China by 20 percent each year until at least 2013. The bulk of the new positions will be in sales, according to CEO Joseph Jimenez. Amy Huang, vice-president and China director of GlaxoSmithKline (GSK), said the company does not intend to cut its budget for China this year - instead it will invest more in developing new medicines and vaccines, including funds for expansion of human resources related to R&D. The UK-headquartered company announced in February it will cut 6,000 jobs this year globally. Pharma health means more jobs The world's second-largest generic medicine company Sandoz said it will recruit more people in China, not only in sales and manufacturing, but also managerial talent. "The reason for the workforce enhancement in China is rapid expansion of these drug companies here," said Peng Haizhu, pharmaceutical analyst of Huatai Securities. Year-on-year sales of Lilly China grew around 30 percent in 2008, while its global business rose 9 percent. GSK achieved a 12 percent growth in sales in emerging markets. China outperformed other emerging markets with a 22 percent increase in sales as global numbers fell by 3 percent. Sales by Novartis Pharmaceuticals in China jumped 29 percent year-on-year to 3.3 billion yuan in 2008, compared with its 6 percent global growth and the company is expecting a 30 percent rise in China this year. AstraZeneca's figures were 25 percent and 7 percent in China and the world respectively
For further details visit at : www.chinadaily.com.cn/bizchina/2009-06/15/content_8283244.htm
s we expect to do a better job reaching patients in central and western areas of China," David Ricks, Lilly China president, told China Business Weekly late last month. But he added Lilly China is growing in all aspects, so new employees will be needed in virtually every function from manufacturing and R&D to accounting and operations. Lilly China is not the only pharmaceutical firm expanding recruitment in China even as global workforce numbers are stagnant or even dropping. Swiss drug maker Novartis Pharmaceuticals expects to increase its 2,700 employees in China by 20 percent each year until at least 2013. The bulk of the new positions will be in sales, according to CEO Joseph Jimenez. Amy Huang, vice-president and China director of GlaxoSmithKline (GSK), said the company does not intend to cut its budget for China this year - instead it will invest more in developing new medicines and vaccines, including funds for expansion of human resources related to R&D. The UK-headquartered company announced in February it will cut 6,000 jobs this year globally. Pharma health means more jobs The world's second-largest generic medicine company Sandoz said it will recruit more people in China, not only in sales and manufacturing, but also managerial talent. "The reason for the workforce enhancement in China is rapid expansion of these drug companies here," said Peng Haizhu, pharmaceutical analyst of Huatai Securities. Year-on-year sales of Lilly China grew around 30 percent in 2008, while its global business rose 9 percent. GSK achieved a 12 percent growth in sales in emerging markets. China outperformed other emerging markets with a 22 percent increase in sales as global numbers fell by 3 percent. Sales by Novartis Pharmaceuticals in China jumped 29 percent year-on-year to 3.3 billion yuan in 2008, compared with its 6 percent global growth and the company is expecting a 30 percent rise in China this year. AstraZeneca's figures were 25 percent and 7 percent in China and the world respectivelyFor further details visit at : www.chinadaily.com.cn/bizchina/2009-06/15/content_8283244.htm
No comments:
Post a Comment